Antigrowth effect of some inhibitors of polyamine synthesis on transplantable prostate cancer

Area of Science:

• Oncology
• Biochemistry
• Pharmacology

Background:

• Polyamines are essential for cell growth and proliferation.
• Elevated polyamine levels are observed in various cancers, including prostate cancer.
• Inhibiting polyamine synthesis is a potential therapeutic strategy for cancer treatment.

Purpose of the Study:

• To evaluate the therapeutic effectiveness of polyamine synthesis inhibitors on transplantable prostate cancer.
• To investigate the efficacy of combining different inhibitors for enhanced antitumor activity.

Main Methods:

• Testing alpha-difluormethylornithine (DFMO), an ornithine decarboxylase inhibitor.
• Testing methylglyoxal-bis[guanylhydrazone] (MGBG), an S-adenosyl-L-methionine decarboxylase (AMDC) inhibitor.
• Evaluating combinations of DFMO and MGBG, and MGBG with 9-B-D-arabinofuranosyladenine.

Main Results:

• Inhibition of ornithine decarboxylase or AMDC by DFMO or MGBG, respectively, demonstrated significant antitumor effects.
• The combination of DFMO and MGBG was more effective than MGBG alone and showed no increased toxicity.
• Combining MGBG with 9-B-D-arabinofuranosyladenine did not enhance the therapeutic effectiveness of MGBG.

Conclusions:

• Inhibitors of polyamine synthesis, particularly DFMO and MGBG, exhibit significant therapeutic potential against prostate cancer.
• Combination therapy with DFMO and MGBG offers an effective and safe strategy for enhancing antitumor responses.
• Targeting polyamine synthesis pathways presents a viable approach for novel prostate cancer treatments.